ALLR 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-15

• On March 3, 2025, the board of directors approved a share repurchase program, with authorization to purchase up to $5 million of the Company’s outstanding shares of common stock over a twelve month period. On February 26, 2026, the board of directors approved a new share repurchase program, with aut…

• On April 27, 2026, the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application covering the Company’s DRP® companion diagnostic specific to stenoparib.

• We generated $0.025 million of service revenue for the three months ended March 31, 2026 from the license of DRP testing services. There was no revenue for the three months ended March 31, 2025.

• For the three months ended March 31, 2026, compared to March 31, 2025

• Research and development expenses decreased $0.1 million primarily due to reduced costs and supplies of the Phase II clinical trial of stenoparib. These expenses are recognized at the time of purchase.

相对上期删除的文字 · 来源:10-Q · 2025-11-14

• On March 3, 2025, the board of directors approved a share repurchase program, with authorization to purchase up to $5 million of the Company’s outstanding shares of common stock. For the three months ended September 30, 2025, the Company repurchased 145,061 shares for an aggregate cost of $140,038 i…

• On July 1, 2025, Jeffrey S. Ervin was appointed to the office of Chief Financial Officer of the Company, replacing Alexander Epshinsky upon his resignation on June 30, 2025.

• On August 26, 2025, the Company announced the FDA granted Fast Track designation status for Stenoparib for the treatment of advanced ovarian cancer. The FDA's Fast Track designation is intended to expedite the development and review of drugs that treat serious conditions and fill an unmet medical ne…

• On September 22, 2025, the Company entered into a Securities Purchase Agreement with a certain accredited investor, pursuant to which the Company agreed to sell the shares and/or prefunded warrants to the investor, in a private placement transaction. The Company agreed to issue and sell 1,562,500 sh…

• For the three months ended September 30, 2025, compared to September 30, 2024

相对上期新增的文字 · 来源:10-Q · 2026-05-15

• There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fiscal quarter ended March 31, 2026, which have materially affected, or are reasonably likely to materially affect, our internal contro…

相对上期删除的文字 · 来源:10-Q · 2025-11-14

• Management has identified material weaknesses in its internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in a company’s internal control over financial reporting such that there is a reasonable possibility that a material misstatement of it…

• The Company plans to update our internal controls and implement new policy and procedures measures to improve internal controls over financial reporting.

• The Company is in process of implementing enhanced review processes to ensure timely identification of appropriate accounting related to all contractual agreements.

• Such material weaknesses and control deficiencies will not be remediated until the Company’s remediation plan has been fully implemented, and it has concluded that its internal controls are operating effectively for a sufficient period of time.

• We can offer no assurance that these initiatives will ultimately have the intended effects.